Regis Healthcare Limited
Regis Healthcare Limited (REG.AX) Financial Performance & Income Statement Overview
Explore the financials of Regis Healthcare Limited (REG.AX), including yearly and quarterly data on income, cash flow, and balance sheets.
Regis Healthcare Limited (REG.AX) Income Statement & Financial Overview
Review Regis Healthcare Limited REG.AX income statement with detailed quarterly and annual figures.
Metric | Q4 2024 | Q2 2024 | Q4 2023 | Q2 2023 |
---|---|---|---|---|
Revenue | $533.98M | $475.66M | $394.72M | $376.76M |
Cost of Revenue | $442.51M | $459.35M | $397.59M | $377.68M |
Gross Profit | $91.47M | $16.31M | -$2.87M | -$910000.00 |
Gross Profit Ratio | $0.17 | $0.03 | -$0.007 | -$0.002 |
R&D Expenses | $0.00 | $0.00 | $0.00 | $0.00 |
SG&A Expenses | $36.82M | $41.82M | $49.15M | $36.46M |
Operating Expenses | $36.82M | $41.82M | $49.15M | $36.46M |
Total Costs & Expenses | $479.33M | $501.17M | $446.74M | $414.13M |
Interest Income | $2.69M | $1.29M | $526000.00 | $179000.00 |
Interest Expense | $50.76M | $40.89M | $6.13M | $36.89M |
Depreciation & Amortization | $65.02M | $63.05M | $63.12M | $63.35M |
EBITDA | $102.21M | $89.24M | $64.46M | $62.92M |
EBITDA Ratio | $0.19 | $0.08 | $0.03 | $0.07 |
Operating Income | $54.65M | -$25.51M | -$52.03M | -$37.37M |
Operating Income Ratio | $0.10 | -$0.05 | -$0.13 | -$0.10 |
Other Income/Expenses (Net) | -$68.14M | -$54.74M | -$30.83M | -$66.11M |
Income Before Tax | -$13.49M | -$14.61M | -$3.89M | -$36.49M |
Income Before Tax Ratio | -$0.03 | -$0.03 | -$0.010 | -$0.10 |
Income Tax Expense | -$4.22M | -$2.47M | -$1.35M | -$10.58M |
Net Income | -$9.27M | -$12.14M | -$2.54M | -$25.91M |
Net Income Ratio | -$0.02 | -$0.03 | -$0.006 | -$0.07 |
EPS | -$0.03 | -$0.04 | -$0.008 | -$0.09 |
Diluted EPS | -$0.03 | -$0.04 | -$0.008 | -$0.09 |
Weighted Avg Shares Outstanding | $301.06M | $300.98M | $300.91M | $300.87M |
Weighted Avg Shares Outstanding (Diluted) | $301.10M | $300.98M | $300.91M | $300.87M |
Over the past four quarters, Regis Healthcare Limited demonstrated steady revenue growth, increasing from $376.76M in Q2 2023 to $533.98M in Q4 2024. Operating income reached $54.65M in Q4 2024, maintaining a consistent 10% margin over recent quarters. Despite fluctuations in R&D and SG&A expenses, EBITDA remained robust at $102.21M, reflecting operational efficiency. Net income rose to -$9.27M, with EPS at -$0.03. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan